139 related articles for article (PubMed ID: 12142637)
1. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
Skogh E; Reis M; Dahl ML; Lundmark J; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):518-26. PubMed ID: 12142637
[TBL] [Abstract][Full Text] [Related]
2. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.
Linnet K; Olesen OV
Ther Drug Monit; 2002 Aug; 24(4):512-7. PubMed ID: 12142636
[TBL] [Abstract][Full Text] [Related]
3. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
Skogh E; Sjödin I; Josefsson M; Dahl ML
J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
Olesen OV; Linnet K
Ther Drug Monit; 1999 Feb; 21(1):87-90. PubMed ID: 10051059
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.
Gex-Fabry M; Balant-Gorgia AE; Balant LP
Ther Drug Monit; 2003 Feb; 25(1):46-53. PubMed ID: 12548144
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication.
Theisen FM; Haberhausen M; Schulz E; Fleischhaker C; Clement HW; Heinzel-Gutenbrunner M; Remschmidt H
Ther Drug Monit; 2006 Dec; 28(6):750-9. PubMed ID: 17164690
[TBL] [Abstract][Full Text] [Related]
7. Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.
An H; Fan H; Chen S; Qi S; Ma B; Shi J; Wang Z; Yang F
J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):255-259. PubMed ID: 33814547
[TBL] [Abstract][Full Text] [Related]
8. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
[TBL] [Abstract][Full Text] [Related]
9. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH
PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777
[TBL] [Abstract][Full Text] [Related]
10. [Monitoring of serum olanzapine during antipsychotic treatment].
Linnet K; Olesen OV
Ugeskr Laeger; 2000 Sep; 162(36):4802-5. PubMed ID: 10994377
[TBL] [Abstract][Full Text] [Related]
11. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model.
Botts S; Diaz FJ; Santoro V; Spina E; Muscatello MR; Cogollo M; Castro FE; de Leon J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1453-8. PubMed ID: 18555573
[TBL] [Abstract][Full Text] [Related]
12. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.
Bergemann N; Frick A; Parzer P; Kopitz J
Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613
[TBL] [Abstract][Full Text] [Related]
14. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
Rao ML; Hiemke C; Grasmäder K; Baumann P;
Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
[TBL] [Abstract][Full Text] [Related]
15. Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.
Ding J; Zhang Y; Zhang Y; Yang L; Zhang S; Cui X; Meng Z; Li Y; Xing H
J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):552-559. PubMed ID: 36286707
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of ziprasidone in a clinical treatment setting.
Chermá MD; Reis M; Hägg S; Ahlner J; Bengtsson F
Ther Drug Monit; 2008 Dec; 30(6):682-8. PubMed ID: 18824954
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Callaghan JT; Bergstrom RF; Ptak LR; Beasley CM
Clin Pharmacokinet; 1999 Sep; 37(3):177-93. PubMed ID: 10511917
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis.
Yin A; Shang D; Wen Y; Li L; Zhou T; Lu W
Eur J Clin Pharmacol; 2016 Aug; 72(8):933-44. PubMed ID: 27117554
[TBL] [Abstract][Full Text] [Related]
19. Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.
Lu ML; Lin CH; Chen YC; Yang HC; Wu TH
PLoS One; 2013; 8(5):e65719. PubMed ID: 23741510
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.
Söderberg MM; Haslemo T; Molden E; Dahl ML
Pharmacogenet Genomics; 2013 May; 23(5):279-85. PubMed ID: 23492908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
